Symeres has acquired DGr Pharma to strengthen its early-stage drug development services and accelerate IND-enabling capabilities for biopharma clients. This strategic deal, backed by Keensight Capital, brings together Symeres’ global contract research, development, and manufacturing expertise with DGr Pharma’s deep regulatory consultancy roots.
Founded in 2018 and headquartered in the Netherlands, DGr Pharma offers pre-clinical and clinical regulatory strategy for biotech and pharmaceutical partners. Its team guides projects through chemical-pharmaceutical development planning, non-clinical study design, clinical trial advice, quality assurance, and regulatory submissions for both small molecules and complex biologics such as antibodies, ADCs, and oligonucleotides.
By adding DGr Pharma’s scientific rigor and regulatory depth, Symeres can now deliver a truly integrated solution that spans the full spectrum of drug discovery and development. Clients will benefit from seamless coordination between early discovery work, pharmacology studies, analytical method development, and first-in-human planning, all under a unified project structure.
DGr Pharma’s pharmacokinetic data analysis services adhere to Good Clinical Practice and Good Laboratory Practice standards, mirroring Symeres’ commitment to quality in its ADME offerings. The combined GLP accreditation ensures high-quality data and regulatory readiness, smoothing the path to IND submission and reducing potential delays in interactions with health authorities.
This acquisition enables Symeres to offer faster timelines and greater consistency across complex development programs. Project teams will leverage shared platforms and standardized procedures, cutting handoff time between discovery, toxicology, and clinical phases. Biopharma partners can expect enhanced transparency, more predictable milestones, and a streamlined roadmap from molecule design to clinical trial entry.
Symeres is a global CRDMO with facilities and teams dedicated to small-molecule research, development, and manufacturing. Keensight Capital, a leading European growth buyout investor, continues to support Symeres’ expansion into high-value services that address evolving industry needs.
Together, Symeres and DGr Pharma are set to redefine early-stage drug development by combining regulatory expertise, advanced analytical capabilities, and a client-centric approach. This partnership marks a significant step toward delivering faster, more efficient paths to clinical evaluation for tomorrow’s breakthrough therapies.
KEY QUOTES:
“This acquisition strengthens our ability to offer truly integrated solutions across the drug discovery and development spectrum. The company enhances our scientific capabilities, allowing us to better support our clients’ evolving needs and reinforce Symeres’ position as a partner of choice in the global biopharma market.”
Guillaume Jetten, CEO of Symeres
“This is an exciting new chapter for DGr Pharma. Joining Symeres provides us with the opportunity to grow our reach and expand the value we bring to clients, particularly in early-stage development. We share Symeres’ commitment to high-quality science, long-term relationships and entrepreneurial ambition and we look forward to being part of the next phase of growth.”
Kees Groen, Founder and CEO of DGr Pharma
“We are proud to support Symeres with this specialized acquisition, which will extend the company’s capabilities into highly complementary services and attractive drug classes. We look forward to continuing to support the Symeres team as they selectively broaden the Company’s offering for their blue-chip biopharma clients.”
Amit Karna, Partner at Keensight Capital
